Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET
December 02 2022 - 7:00AM
via InvestorWire -- Lantern Pharma Inc (Nasdaq: LTRN), a
clinical stage biopharmaceutical company using its proprietary
RADR® artificial intelligence ("A.I.") and machine learning
(“M.L.”) platform to transform the cost, pace, and timeline of
oncology drug discovery and development, today announces that Panna
Sharma, CEO and President, will present at the RHK Capital
Disruptive Growth Conference in New York City.
Event |
RHK Capital Disruptive Growth Conference |
Date |
December 5, 2022 |
Time |
12:00 p.m. ET |
Webcast Link |
https://wsw.com/webcast/rhk2/ltrn/1625568 |
The RHK Capital Disruptive Growth Conference
will feature leading C-suite executives and senior management of up
to 30 growth-oriented and disruptive companies to meet with
seasoned institutional investors, accredited investors,
representatives of family offices, market analysts and financial
advisors, as well as broker-dealer wealth managers and select RHK
clients.
To learn more and submit a registration request,
visit http://disruptnyc.com/
About Lantern Pharma:Lantern
Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused
biopharmaceutical company leveraging its proprietary RADR® A.I. and
machine learning platform to discover biomarker signatures that
identify patients most likely to respond to its pipeline of
genomically-targeted therapeutics. Lantern is currently developing
four drug candidates and an ADC program across eleven disclosed
tumor targets, including two phase 2 programs. By targeting drugs
to patients whose genomic profile identifies them as having the
highest probability of benefiting from the drug, Lantern's approach
represents the potential to deliver best-in-class outcomes.
Contact:Nicole LeberInvestor
Relations Associateir@lanternpharma.com
Please find more information at:Website:
www.lanternpharma.comLinkedIn:
https://www.linkedin.com/company/lanternpharma/Twitter:
@lanternpharmaMonthly Newsletter: Sign-up here
Forward-looking Statements:This
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements include, among other things,
statements relating to: future events or our future financial
performance; the potential advantages of our RADR® platform in
identifying drug candidates and patient populations that are likely
to respond to a drug candidate; our strategic plans to advance the
development of our drug candidates and antibody drug conjugate
(ADC) development program; estimates regarding the development
timing for our drug candidates and ADC development program;
expectations and estimates regarding clinical trial timing and
patient enrollment; our research and development efforts of our
internal drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug candidates and
our plans to discover and develop drug candidates and to maximize
their commercial potential by advancing such drug candidates
ourselves or in collaboration with others. Any statements that are
not statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "model," "objective," "aim," "upcoming," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® A.I. platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the Securities and Exchange Commission on March 10,
2022. You may access our Annual Report on Form 10-K for the year
ended December 31, 2021 under the investor SEC filings tab of our
website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
Wire Service Contact:InvestorWire (IW) Los
Angeles, Californiawww.InvestorWire.com212.418.1217
OfficeEditor@InvestorWire.com
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024